TY - JOUR
T1 - The Dance Between Tumor Molecular Biology and Antitumor Immune Response
AU - Margolin, Kim A.
N1 - Publisher Copyright:
©2023 American Association for Cancer Research.
PY - 2024/1/17
Y1 - 2024/1/17
N2 - When the cyclin kinase 4/6 inhibitor abemaciclib was sequenced with PD-1 blockade in mostly immunologically "cold" murine models, enhanced immune-mediated antitumor effects-including increased lifespan, recruitment of CD8 cells to tumor, reduction of regulatory T-cell and immunosuppressive cytokines in tumor, increased tumor antigen presentation, and broadening of the T-cell receptor repertoire-were achieved in both cutaneous and brain metastases. See related article by Nayyar et al., p. 420.
AB - When the cyclin kinase 4/6 inhibitor abemaciclib was sequenced with PD-1 blockade in mostly immunologically "cold" murine models, enhanced immune-mediated antitumor effects-including increased lifespan, recruitment of CD8 cells to tumor, reduction of regulatory T-cell and immunosuppressive cytokines in tumor, increased tumor antigen presentation, and broadening of the T-cell receptor repertoire-were achieved in both cutaneous and brain metastases. See related article by Nayyar et al., p. 420.
UR - http://www.scopus.com/inward/record.url?scp=85182725303&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-23-2642
DO - 10.1158/1078-0432.CCR-23-2642
M3 - Article
C2 - 37988415
AN - SCOPUS:85182725303
SN - 1078-0432
VL - 30
SP - 257
EP - 259
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -